• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bridgebio Pharma Inc (NQ: BBIO )

    25.96 -0.77 (-2.88%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,657,526
    Open 26.44
    Bid (Size) 25.80 (1)
    Ask (Size) 26.58 (4)
    Prev. Close 26.73
    Today's Range 25.80 - 26.84
    52wk Range 21.62 - 44.32
    Shares Outstanding 160,500,999
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
    BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study demonstrated increased cortisol production and reductions in key... 
    Via Benzinga

    Performance

    YTD
    -35.82%
    -35.82%
    1 Month
    +3.14%
    +3.14%
    3 Month
    -4.03%
    -4.03%
    6 Month
    -9.33%
    -9.33%
    1 Year
    -7.75%
    -7.75%

    More News

    Read More
    BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Patchy And Still Patchy In The Short Term
    Via Talk Markets
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Why Is BridgeBio Pharma Stock Trading Higher On Friday?
    Via Benzinga
    BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Marvell Technology Posts Upbeat Sales, Joins MongoDB, Intel, MINISO Group And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
    Via Benzinga
    BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma to Participate in September Investor Events
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BBIO Stock Earnings: BridgeBio Pharma Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Masters In Trading - Saturday, June 22
    Via Talk Markets
    BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.